Variables | All patients with SLE |
---|---|
(n = 107) | |
*Except where indicated otherwise, values are the mean (SD). | |
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ECLAM, European Consensus Lupus Activity Measurement; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; ESR, erythrocyte sedimentation rate, normal <10 mm/1st h; CRP, C reactive protein, normal <8 mg/l; serum creatinine, normal 60–110 μmol/l; creatinine clearance, (140−age (years)) × body weight (kg)/(serum creatinine (μmol/l)×R), for men R = 0.86 and for women R = 1.01; BMI, body mass index; hypertension: defined by a physician diagnosis and/or treatment with anti-hypertensive drugs; diabetes: defined by a physician diagnosis and/or the use of anti-diabetic drugs; LDL cholesterol, total cholesterol—HDL cholesterol—(0.45×triglycerides); ADMA, asymmetric dimethylarginine. | |
Demographic variables | |
Female sex (%) | 92 |
Age (years) | 41 (13) |
White (%) | 76 |
Clinical variables | |
Disease duration (years) | 6.7 (6.7) |
SLEDAI | 4.9 (4.1) |
ECLAM | 3.1 (1.7) |
SDI (modified) | 1.3 (1.7) |
Corticosteroid use ever (%) | 81 |
Current corticosteroid use (%) | 52 |
Duration of corticosteroid use (months) | 62 (69) |
Current daily prednisone dose (mg) | 13 (12) |
Hydroxychloroquine use ever (%) | 87 |
ESR (mm/1st h) | 25 (24) |
CRP (mg/l) | 11 (16) |
Serum creatinine (μmol/l) | 88 (20) |
Creatinine clearance (ml/min) | 88 (26) |
Anti-dsDNA (IE/ml) | 34 (67) |
Potential risk factors for arterial cardiovascular disease | |
BMI (kg/m2) | 25 (6) |
Current smoker (%) | 22 |
Ever smoker (%) | 54 |
Hypertension (%) | 31 |
Diabetes (%) | 8 |
Serum HDL cholesterol (mmol/l) | 1.44 (0.37) |
Serum LDL cholesterol (mmol/l) | 2.8 (1.0) |
Serum triglycerides (mmol/l) | 1.25 (0.65) |
Serum homocysteine (μmol/l) | 11.7 (4.4) |
Plasma ADMA (μmol/l) | 0.44 (0.08) |